49 [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict WW in mccRCC patients Table 1. Baseline characteristics and demographics All patients Baseline [18F]FDG-uptake** Baseline [89Zr)Zr-DFO-girentuximab uptake** (n = 40) Low uptake group (n = 20) High uptake group (n = 20) Low uptake group (n = 20) High uptake group (n=20) Age, years (mean ± SD) 65.8 (± 9.1) 67.4 (± 8.5) 64.2 (± 9.7) 66.7 (± 7.9) 64.9 (± 10.4) Male 30 (75) 16 (80) 14 (70) 17 (85) 13 (65) Synchronous metastases* 19 (48) 9 (45) 10 (50) 7 (35) 12 (60) Nephrectomy 35 (88) 19 (95) 16 (80) 20 (100) 15 (75) Hb <LLN 13 (33) 7 (35) 6 (30) 4 (20) 9 (45) Neutrophils >ULN 2 (5) 1 (5) 1 (5) 1 (5) 1 (5) Platelets >ULN 2 (5) 0 (0) 2 (10) 1 (5) 1 (5) Calcium >ULN 1 (3) 0 (0) 1 (5) 1 (5) 0 (0) Karnofsky Performance Score < 80 1 (3) 1 (5) 0 (0) 1 (5) 0 (0) Interval < 1 year between primary diagnosis and first metastases 21 (53) 10 (50) 11 (55) 7 (35) 14 (70) IMDC 0 14 (35) 8 (40) 6 (30) 11 (55) 3 (15) 1 12 (30) 5 (25) 7 (35) 3 (15) 9 (45) 2 14 (35) 7 (35) 7 (35) 6 (30) 8 (40) Number of organ sites (on CT-scan) ◊ 1 14 (35) 12 (60) 2 (10) 11 (55) 3 (15) 2 16 (40) 5 (25) 11 (55) 8 (40) 8 (40) 3 8 (20) 2 (10) 6 (30) 1 (5) 7 (35) 4 2 (5) 1 (5) 1 (5) - 2 (10) 3
RkJQdWJsaXNoZXIy MTk4NDMw